Program
relatlimab
Also written as “Relatlimab”, “Nivolumab + Relatlimab” and “relatlimab+nivolumab”.
Its studies are mostly in Melanoma · Carcinoma, Non-Small-Cell Lung · Neoplasms · Stomach Neoplasms · Carcinoma, Hepatocellular, led by Bristol-Myers Squibb.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 195 open or running | phase 4since Mar 5, 2026 | Sep 25, 2013 | May 26, 2029phase 4 · NCT07459543 |
Also a collaborator on its studies: Exelixis, Novartis, clovis-oncology-inc, Johnson & Johnson, Halozyme Therapeutics and Ono Pharmaceutical.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Sep 25, 2013.
- Dec 15, 2016Phase 2 study in Advanced CancerNCT02996110 · 182 enrolled · United States, Australia, Austria and more
- Nov 6, 2017Phase 1 study in Advanced CancerNCT03335540 · 20 enrolled · United States
- Oct 9, 2018Phase 2 study in Stomach NeoplasmsNCT03704077 · United States, Argentina, Australia and more
- Apr 1, 2019Phase 2 study in NeoplasmsNCT03899155 · 1,500 planned · United States, Argentina, Australia and more
- Jun 5, 2019Phase 1 study in MelanomaNCT03978611 · 11 enrolled · United States, Belgium, Canada and more
- Nov 5, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungNCT04623775 · 468 enrolled · United States, Argentina, Australia and more
- Aug 4, 2021Phase 3 study in MelanomaNCT05002569 · 1,093 enrolled · United States, Argentina, Australia and more
- Feb 15, 2022Phase 2 study in Lymphoma, Non-HodgkinNCT05255601 · 5 enrolled · United States, Australia, France and more
- Apr 13, 2022Phase 2 study in Carcinoma, HepatocellularNCT05337137 · 82 enrolled · United States, Australia, Canada and more
- Aug 10, 2022Phase 1 study in Advanced Solid TumorsNCT05498480 · 6 enrolled · China
- Nov 15, 2022Phase 3 study in MelanomaNCT05625399 · 579 enrolled · United States, Australia, Austria and more
- Oct 20, 2023Phase 2 study in MelanomaNCT06101134 · 100 enrolled · United States, Chile, Greece and more
- Aug 16, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06561386 · 1,000 planned · United States, Argentina, Australia and more
- Mar 5, 2026Phase 4 study in MelanomaNCT07459543 · 40 planned · India
Ahead
- May 26, 2029Primary completion: phase 4 study in MelanomaNCT07459543
- Aug 25, 2029Primary completion: phase 2 study in NeoplasmsNCT03899155
- Jul 30, 2030Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06561386
TargetBeta
“A monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3), ”NCIt, by rule
“Lymphocyte activation gene 3 protein inhibitor”ChEMBL 37, by rule
Other programs on LAG3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| fianlimabrule | Regeneron Pharmaceuticals | phase 3 | 10 |
| Anti-PD-1/LAG-3 Bispecific Antibody AK129rule | Akeso | phase 2 | 4 |
| TQB2252 | Sino Biopharmaceutical | phase 1 | 1 |
Studies
All 19 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07459543Melanoma · India | 4 | Not yet recruiting | May 26, 2029 | 40 |
| NCT06561386Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Recruiting | Jul 30, 2030 | 1,000 |
| NCT06101134Melanoma · United States, Chile, Greece and more | 2 | Active, not recruiting | Apr 10, 2025 | 100 |
| NCT05625399Melanoma · United States, Australia, Austria and more | 3 | Active, not recruiting | Aug 4, 2025 | 579 |
| NCT05498480Advanced Solid Tumors · China | 1 | Completed | Jan 18, 2024 | 6 |
| NCT05337137Carcinoma, Hepatocellular · United States, Australia, Canada and more | 2 | Completed | Jul 5, 2025 | 82 |
| NCT05255601Lymphoma, Non-Hodgkin · United States, Australia, France and more | 2 | Terminated | Dec 3, 2025 | 5 |
| NCT05002569Melanoma · United States, Argentina, Australia and more | 3 | Terminated | Dec 16, 2024 | 1,093 |
| NCT04623775Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 2 | Completed | Jan 11, 2024 | 468 |
| NCT03978611Melanoma · United States, Belgium, Canada and more | 1 | Terminated | Jul 26, 2023 | 11 |
| NCT03899155Neoplasms · United States, Argentina, Australia and more | 2 | Recruiting | Aug 25, 2029 | 1,500 |
| NCT03704077Stomach Neoplasms · United States, Argentina, Australia and more | 2 | Withdrawn | Feb 27, 2022 | 0 |
| NCT03335540Advanced Cancer · United States | 1 | Completed | Mar 31, 2021 | 20 |
| NCT02996110Advanced Cancer · United States, Australia, Austria and more | 2 | Completed | Nov 23, 2021 | 182 |
| NCT02966548Neoplasms · Japan | 1 | Completed | Jul 9, 2024 | 35 |
| NCT02935634Advanced Gastric Cancer · United States, Australia, Canada and more | 2 | Completed | May 11, 2022 | 190 |
| NCT02750514Advanced Cancer · United States, Australia, Austria and more | 2 | Terminated | Jan 29, 2020 | 295 |
| NCT02061761Hematologic Neoplasms · United States, Canada | 2 | Completed | Feb 16, 2022 | 106 |
| NCT01968109Neoplasms by Site · United States, Australia, Austria and more | 2 | Completed | May 22, 2024 | 1,482 |
How it is read
Names in the registry
- “Relatlimab”, 13 entries
- “Nivolumab + Relatlimab”, 3 entries
- “relatlimab+nivolumab”, 1 entry
- “relatlimab+nivolumab+rHuPH20”, 1 entry
- “Nivolumab + Relatlimab Fixed Dose Combination”, 1 entry
Conditions, from the studies’ own filings
- Melanoma, 5 studies
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Neoplasms, 2 studies
- Stomach Neoplasms, 2 studies
- Carcinoma, Hepatocellular, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.